The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Momenta Pharmaceuticals Inc

Nasdaq: MNTA
Last

(U.S.) $21.74

Today's change0.00 0.00%
Updated July 6 4:00 PM EDT. Delayed by at least 15 minutes.
 

Momenta Pharmaceuticals Inc

Nasdaq: MNTA
Last

(U.S.) $21.74

Today's change0.00 0.00%
Updated July 6 4:00 PM EDT. Delayed by at least 15 minutes.

Momenta Pharmaceuticals Inc closed at (U.S.)$21.74.

Shares have lost 3.72% over the last five days, but have gained 80.56% over the last year to date. This security has outperformed the S&P 500 by 75.62% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $21.74
  • High--
  • Low--
  • Bid / Ask-- / --
  • YTD % change+80.56%
  • Volume0
  • Average volume (10-day)918,197
  • Average volume (1-month)1,010,749
  • Average volume (3-month)1,223,362
  • 52-week range(U.S.) $9.38 to (U.S.) $25.56
  • Beta1.86
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.78
Updated July 6 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-186.13%

Although this company's net profit margin is negative, it is above the industry average and implies that Momenta Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.60%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue921911
Total other revenue--------
Total revenue921911
Gross profit--------
Total cost of revenue--------
Total operating expense31373937
Selling / general / administrative8111111
Research & development23262826
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-22-16-29-26
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-22-16-29-26
Income after tax-22-16-29-26
Income tax, total----00
Net income-22-16-29-26
Total adjustments to net income--------
Net income before extra. items-22-16-29-26
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-22-16-29-26
Inc. avail. to common incl. extra. items-22-16-29-26
Diluted net income-22-16-29-26
Dilution adjustment--000
Diluted weighted average shares54525251
Diluted EPS excluding extraordinary itemsvalue per share-0.40-0.31-0.56-0.51
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.40-0.31-0.56-0.51